A Phase 2 Proof-of-Concept Study of Gevokizumab in Active Inflammatory, Erosive Osteoarthritis of the Hand
Latest Information Update: 30 Apr 2014
Price :
$35 *
At a glance
- Drugs Gevokizumab (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- 03 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record .
- 24 Sep 2013 Planned end date changed from 30 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 07 Aug 2013 Top-line results are expected in October 2013, according to an XOMA media release.